Stockscreener 앱 받기
5.31
33.08%
1.32
시간 외 거래:
5.21
-0.10
-1.88%
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
Aldeyra Therapeutics Target of Unusually Large Options Trading (NASDAQ:ALDX) - MarketBeat
Buy Rating for Aldeyra Therapeutics: Confidence in Reproxalap’s Approval and Financial Upside - TipRanks
Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision? - Stocktwits
ALDX: FDA extends reproxalap NDA review by 90 days after requiring field trial CSR submission - TradingView — Track All Markets
Why Is Aldeyra Therapeutics Stock Falling Tuesday?Aldeyra Therapeutics (NASDAQ:ALDX) - Benzinga
Aldeyra Therapeutics (ALDX) Faces FDA Review Delay for Reproxala - GuruFocus
Aldeyra stock drops on FDA delay for lead drug (ALDX:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Aldeyra Therapeutics Faces FDA PDUFA Date Extension - TipRanks
Aldeyra Says FDA Extends Action Date for Potential Dry Eye Disease Treatment; Shares Down Pre-Bell - marketscreener.com
Aldeyra Therapeutics Announces PDUFA Extension for Reproxalap NDA - TradingView — Track All Markets
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Aldeyra (ALDX) Receives Extended FDA Action Date for Reproxalap NDA - GuruFocus
Aldeyra (Nasdaq: ALDX) PDUFA review of reproxalap dry eye NDA extended to Mar. 2026 - Stock Titan
Aldeyra Therapeutics announces PDUFA extension of the new drug application of Reproxalap for the treatment of dry eye disease - marketscreener.com
683 Capital Management LLC Has $4.14 Million Stake in Aldeyra Therapeutics, Inc. $ALDX - MarketBeat
Adversity is less terrifying than hope: Aldeyra Therapeutics Inc (ALDX) - setenews.com
Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) recent 10% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance
Aldeyra Therapeutics, Inc. $ALDX Shares Sold by Kennedy Capital Management LLC - MarketBeat
Winners Losers: Will Aldeyra Therapeutics Inc stock maintain momentum in 2025 - BỘ NỘI VỤ
It makes sense and dollars to buy Aldeyra Therapeutics Inc (ALDX) stock - setenews.com
Aldeyra Therapeutics Inc (137.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Aldeyra Therapeutics Inc. stock oversold or undervaluedCEO Change & Smart Allocation Stock Reports - Newser
Will Aldeyra Therapeutics Inc. stock maintain momentum in 2025Bull Run & Free Technical Confirmation Trade Alerts - moha.gov.vn
Can Aldeyra Therapeutics Inc. stock deliver surprise earnings beatChart Signals & Long-Term Capital Growth Strategies - moha.gov.vn
Will Aldeyra Therapeutics Inc. stock benefit from infrastructure spendingJuly 2025 Analyst Calls & Fast Entry and Exit Trade Plans - moha.gov.vn
Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet? - simplywall.st
Kennondale Capital Management LLC Sells 94,551 Shares of Aldeyra Therapeutics, Inc. $ALDX - MarketBeat
Why retail investors favor Aldeyra Therapeutics Inc. stock2025 Short Interest & Free Growth Oriented Trading Recommendations - newser.com
Aldeyra Therapeutics Inc Stock Analysis and ForecastContrarian Investment Ideas & Small Investment Trading Tips - earlytimes.in
The time has not yet come to remove your chips from the table: Aldeyra Therapeutics Inc (ALDX) - Setenews
Dry Eye Disease Market Size was ~USD 3.76 Billion in 2023 and expected to Grow by 2034, Analysed DelveInsight - Barchart.com
HC Wainwright Has Bullish Estimate for ALDX FY2025 Earnings - Defense World
What sentiment indicators say about Aldeyra Therapeutics Inc. stockJuly 2025 News Drivers & AI Based Buy/Sell Signal Reports - newser.com
Intraday pattern recognizer results for Aldeyra Therapeutics Inc.July 2025 Closing Moves & Daily Profit Maximizing Trade Tips - newser.com
Aldeyra Therapeutics Inc. stock daily chart insightsTrend Reversal & AI Forecast Swing Trade Picks - newser.com
Understanding Aldeyra Therapeutics Inc.’s price movement - newser.com
Live market analysis of Aldeyra Therapeutics Inc.CEO Change & Short-Term High Return Ideas - newser.com
How Aldeyra Therapeutics Inc. stock performs in weak economyGap Down & Weekly Market Pulse Alerts - newser.com
Why Aldeyra Therapeutics Inc. stock is in analyst buy zonePortfolio Update Summary & High Conviction Buy Zone Alerts - newser.com
Can a trend reversal in Aldeyra Therapeutics Inc. lead to recoveryPortfolio Risk Report & Fast Exit and Entry Trade Guides - newser.com
Applying Wyckoff theory to Aldeyra Therapeutics Inc. stock2025 Market Trends & Daily Growth Stock Investment Tips - newser.com
Brokers Offer Predictions for ALDX Q1 Earnings - Defense World
What candlestick patterns are forming on Aldeyra Therapeutics Inc.Market Growth Report & Risk Managed Trade Strategies - newser.com
Aldeyra Therapeutics Inc.’s volatility index tracking explainedMarket Performance Recap & Real-Time Volume Surge Alerts - newser.com
Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry EyeSlideshow (NASDAQ:ALDX) 2025-11-16 - Seeking Alpha
Sentiment analysis tools applied to Aldeyra Therapeutics Inc.July 2025 Recap & Weekly Market Pulse Alerts - newser.com
Smart tools for monitoring Aldeyra Therapeutics Inc.’s price actionWeekly Trading Summary & AI Forecast Swing Trade Picks - newser.com
0.39%
1.90%
자본화:
|
볼륨(24시간):